Pharming Group N.V. - ADR Forecast, price target & analysts
$8.21
6.76%
yesterday
Nasdaq,
Apr 07, 09:30 pm CET
Pharming Group N.V. - ADR Target price 2025 - Analyst rating & recommendation
Powered by
Pharming Group N.V. - ADR Classifications & Recommendation:
Buy
100%
Pharming Group N.V. - ADR Price Target
| Target Price | $24.84 |
| Price | $8.11 |
| Potential |
206.32%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Pharming Group N.V. - ADR 2026 .
The average Pharming Group N.V. - ADR target price is $24.84.
This is
206.32%
register free of charge
$39.00
380.89%
register free of charge
$15.12
86.40%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Pharming Group N.V. - ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2026 of
206.32%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 296.68 | 316.74 |
| 20.75% | 6.76% | |
| EBITDA Margin | 2.48% | 1.28% |
| 155.21% | 48.40% |
6 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2025 . The average Pharming Group N.V. - ADR sales estimate is
$317m
Unlock
6.79%
higher
Unlock
$334m
12.48%
Unlock
$290m
2.18%
Unlock
This results in the following potential growth metrics:
4 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2025. The average Pharming Group N.V. - ADR EBITDA estimate is
$4.1m
Unlock
23.60%
lower
Unlock
$73.3m
1,277.34%
Unlock
$-47.8m
998.50%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 1.57 |
Current Pharming Group N.V. - ADR Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Dec 15 2024 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Dec 15 2024 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Dec 02 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
